Umoja Biopharma Announces Resignation of Board Chair Clay B. Siegall
SEATTLE, May 11, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. announced today Clay B. Siegall, Ph.D. agreed to the Company’s request to resign from Umoja’s board of directors, effective immediately.
Andy Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja said, “We do not expect Dr. Siegall’s absence from the Board to impact day-to-day activities as we continue to carry out the important work of creating curative treatments for solid tumors and blood cancers.”
Scharenberg assumes the role of interim Board Chair.
About Umoja Biopharma, Inc.
Cautionary Note Regarding Forward-Looking Statements